Curocell’s Homegrown CAR-T Therapy Rimqarto Lands Spotlight in Top Hematology Journal Blood
Curocell, a South Korean clinical-stage biotech company specializing in chimeric antigen receptor T-cell (CAR-T) therapies, announced on June 15 that...
Powered by 